Reflex workflows preserve targeted testing inside sequencing-first guidelines
Guideline movement toward broad molecular profiling looked like an extinction event for targeted assays, and the practical response has been a workflow rather than a surrender. Centres test common alterations first, start therapy immediately when one is found, and send the remainder for sequencing. Roughly 44% of cases proceed that way, which means targeted testing happens on close to every patient while sequencing happens on rather fewer. The workflow was not designed; it emerged because turnaround, tissue quantity and reimbursement all pushed clinicians toward it independently. It also means targeted volume is far more durable than displacement forecasts assumed. Adjacent demand is captured in the lung cancer surgery market, which MMA expects to grow from USD 4.6 billion in 2025 to USD 10.3 billion by 2036.
Market Impact: Actionable alterations reaching 62%








